Skip to content

Allphase Pharma Consulting, LLC

A Professional Service Provider for the Pharma Industry

Allphase Pharma Consulting, LLC
Menu

Primary menu

  • CONTACT
  • BLOGS
    • The Viewpoint
    • The News
    • Recent Literature
    • Did you know…?
    • QIDP Antibiotics
  • LEGAL
  • WELCOME

Secondary menu

  • The News
  • The Viewpoint
  • Did you know…?
  • Recent Literature
  • QIDP Antibiotics

Tag Archives: Synagis

There is Momentum Building for RSV Therapeutics

Posted on December 3, 2015 by Harald — No Comments ↓

Sometimes – for no obvious reason – there is a flurry of publications from a particular area which has been quiet for a long time.  RSV is such an area where new drug development had a hard time getting started.  There was always the lure of big money: an infection Continue reading There is Momentum Building for RSV Therapeutics→

Share this:

  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to print (Opens in new window) Print
  • Click to email a link to a friend (Opens in new window) Email
  • Click to share on WhatsApp (Opens in new window) WhatsApp

Like this:

Like Loading...
Posted in Recent Literature, The News, The Viewpoint | Tagged AIDAC, AL-8176, Alios, Allphase Pharma Consulting, ALS-008176, antibiotic blog, Antiviral Drugs Advisory Committee, AstaZeneca, FDA rejection, Gilead, GS-5806, Harald Reinhart, Johnson & Johnson, mAb, MEDI-524, MedImmune, Motavizumab, Novavax, Numax, Numax efficacy, palivizumab, respiratory syncytial virus, RSV, Synagis | Leave a reply

Go back

Your message has been sent

Rating(required)
Warning

Footer Menu

Footer menu

  • CONTACT
  • BLOGS
  • LEGAL
  • WELCOME
  • Email
Copyright © 2026 Allphase Pharma Consulting, LLC. All Rights Reserved.
Theme: Catch Box by Catch Themes
Scroll Up
%d